Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 10/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.45 |
| ▸ | MEN1 | O00255 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2263342 | 1.00 | HDAC3 (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10003610 | 0.71 | EPHX2 (0.58) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2265846 | 0.71 | KDM4E (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8002336 | 0.70 | HDAC3 (0.52) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL14995354 | 0.69 | MAPT (0.61) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1135019 | 0.67 | KDM4E (0.53) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4986332 | 0.67 | MAPT (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2262880 | 0.66 | KMT2A (0.38) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL2262877 | 0.66 | KMT2A (0.38) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL19633685 | 0.66 | ALDH1A1 (0.49) | HDAC6MAPTKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440674-B2 | Substituted pyrimidine compounds as RAF inhibitors and methods of use | AMGEN INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440674-B2 | Substituted pyrimidine compounds as RAF inhibitors and methods of use | AMGEN INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440674-B2 | Substituted pyrimidine compounds as RAF inhibitors and methods of use | AMGEN INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-1976836-B9 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC (US) | 2013-02-06 | — | — | EP | disclosed |
| EP-1976836-B1 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-1976836-B1 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-2481729-A1 | Nintrogen-containing bicyclic heteroaryl compounds for the treatment of RAF protein kinase-mediated diseases | Amgen Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20110251199-A1 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251199-A1 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251199-A1 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-7989461-B2 | Substituted quinazolinamine compounds for the treatment of cancer | AMGEN INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989461-B2 | Substituted quinazolinamine compounds for the treatment of cancer | AMGEN INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989461-B2 | Substituted quinazolinamine compounds for the treatment of cancer | AMGEN INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007076092-A2 | NITROGEN- CONTAINING BICYCLIC HETROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC. (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251199-A1 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS AND METHODS OF USE | BRAF, RAF1, NRAS | HDAC3 1010/4885HDAC4 1368/4885HDAC1 773/4885 |
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | BRAF, NRAS, RAF1 | HDAC3 939/4885HDAC4 1183/4885HDAC1 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.